Nuvation Bio Inc. (NUVB)
Nuvation Bio Statistics
Share Statistics
Nuvation Bio has 338.67M shares outstanding. The number of shares has increased by 36.62% in one year.
| Shares Outstanding | 338.67M |
| Shares Change (YoY) | 36.62% |
| Shares Change (QoQ) | 0.33% |
| Owned by Institutions (%) | 72.27% |
| Shares Floating | 226.88M |
| Failed to Deliver (FTD) Shares | 43.12K |
| FTD / Avg. Volume | 1.57% |
Short Selling Information
The latest short interest is 30.81M, so 9.1% of the outstanding shares have been sold short.
| Short Interest | 30.81M |
| Short % of Shares Out | 9.1% |
| Short % of Float | 12.73% |
| Short Ratio (days to cover) | 8.13 |
Valuation Ratios
The PE ratio is -1.26 and the forward PE ratio is -3.5. Nuvation Bio's PEG ratio is 0.
| PE Ratio | -1.26 |
| Forward PE | -3.5 |
| PS Ratio | 90.81 |
| Forward PS | 2 |
| PB Ratio | 1.54 |
| P/FCF Ratio | -5.48 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Nuvation Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.04, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.04 |
| Quick Ratio | 9.04 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.07 |
| Interest Coverage | -1737.91 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $35.79K |
| Profits Per Employee | $-2.58M |
| Employee Count | 220 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -30.58% in the last 52 weeks. The beta is 1.47, so Nuvation Bio's price volatility has been higher than the market average.
| Beta | 1.47 |
| 52-Week Price Change | -30.58% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 2.54 |
| Relative Strength Index (RSI) | 66.02 |
| Average Volume (20 Days) | 2.75M |
Income Statement
In the last 12 months, Nuvation Bio had revenue of 7.87M and earned -567.94M in profits. Earnings per share was -2.11.
| Revenue | 7.87M |
| Gross Profit | 795K |
| Operating Income | -592.63M |
| Net Income | -567.94M |
| EBITDA | -566.91M |
| EBIT | -567.6M |
| Earnings Per Share (EPS) | -2.11 |
Balance Sheet
The company has 35.72M in cash and 8.91M in debt, giving a net cash position of 26.81M.
| Cash & Cash Equivalents | 35.72M |
| Total Debt | 8.91M |
| Net Cash | 26.81M |
| Retained Earnings | -910.74M |
| Total Assets | 540.63M |
| Working Capital | 468.01M |
Cash Flow
In the last 12 months, operating cash flow was -130.41M and capital expenditures -162K, giving a free cash flow of -130.57M.
| Operating Cash Flow | -130.41M |
| Capital Expenditures | -162K |
| Free Cash Flow | -130.57M |
| FCF Per Share | -0.49 |
Margins
Gross margin is 10.1%, with operating and profit margins of -7527.33% and -7213.76%.
| Gross Margin | 10.1% |
| Operating Margin | -7527.33% |
| Pretax Margin | -7213.76% |
| Profit Margin | -7213.76% |
| EBITDA Margin | -7200.75% |
| EBIT Margin | -7527.33% |
| FCF Margin | -1658.52% |
Dividends & Yields
NUVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NUVB is $10, which is 340.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 340.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 0.92 |
| Piotroski F-Score | 2 |